{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:49:55Z","timestamp":1794412195002,"version":"4.9.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-01147-4","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:27:07Z","timestamp":1758706027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9977-6724","authenticated-orcid":false,"given":"Christian J.","family":"Maine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Picarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki J.","family":"Miyake-Stoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Essink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Somodevilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Geall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelanna","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinaz","family":"Aliahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"1147_CR1","unstructured":"Research, C. for B. E. and. Biological approvals by Year. (FDA, 2025)."},{"key":"1147_CR2","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1126\/science.abj4176","volume":"373","author":"A Pegu","year":"2021","unstructured":"Pegu, A. et al. Durability of mRNA-1273 vaccine\u2013induced antibodies against SARS-CoV-2 variants. Science 373, 1372\u20131377 (2021).","journal-title":"Science"},{"key":"1147_CR3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","volume":"57","author":"K Srivastava","year":"2024","unstructured":"Srivastava, K. et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity 57, 587\u2013599 (2024).","journal-title":"Immunity"},{"key":"1147_CR4","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMc2115596","volume":"385","author":"AY Collier","year":"2021","unstructured":"Collier, A. Y. et al. Differential kinetics of immune responses elicited by covid-19 Vaccines. N. Engl. J. Med. 385, 2010\u20132012 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR5","first-page":"ae4e61b0","volume":"18","author":"C Linnane","year":"2024","unstructured":"Linnane, C. Moderna\u2019s stock falls after biotech\u2019s RSV vaccine trails rivals after 18 months. MarketWatch 18, ae4e61b0 (2024).","journal-title":"MarketWatch"},{"key":"1147_CR6","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1056\/NEJMc2311560","volume":"391","author":"EE Walsh","year":"2024","unstructured":"Walsh, E. E. et al. RENOIR Trial \u2014 RSVpreF vaccine efficacy over two seasons. N. Engl. J. Med. 391, 1459\u20131460 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR7","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/cid\/ciae010","volume":"78","author":"MG Ison","year":"2024","unstructured":"Ison, M. G. et al. Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 78, 1732\u20131744 (2024).","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"1147_CR8","unstructured":"CDC. ACIP Presentation Slides: June 26-28, 2024 Meeting. Advisory Committee on Immunization Practices (ACIP) https:\/\/www.cdc.gov\/acip\/meetings\/presentation-slides-june-26-28-2024.html (ACIP, 2024)."},{"key":"1147_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1473-3099(24)00060-4","volume":"24","author":"Y Oda","year":"2024","unstructured":"Oda, Y. et al. Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2. Lancet Infect. Dis. 24, 341\u2013343 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1147_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39053-9","volume":"14","author":"CD Palmer","year":"2023","unstructured":"Palmer, C. D. et al. GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for \u22656 months in previously-vaccinated older adults. Nat. Commun. 14, 3274 (2023).","journal-title":"Nat. Commun."},{"key":"1147_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jinf.2022.04.018","volume":"84","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. J. Infect. 84, 795\u2013813 (2022).","journal-title":"J. Infect."},{"key":"1147_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-55843-9","volume":"16","author":"CJ Maine","year":"2025","unstructured":"Maine, C. J. et al. Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers. Nat. Commun. 16, 456 (2025).","journal-title":"Nat. Commun."},{"key":"1147_CR13","doi-asserted-by":"publisher","first-page":"e0003709","DOI":"10.1371\/journal.pntd.0003709","volume":"9","author":"K Hampson","year":"2015","unstructured":"Hampson, K. et al. Estimating the global burden of endemic canine rabies. PLoS Negl. Trop. Dis. 9, e0003709 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1147_CR14","unstructured":"NIAID Biodefense Pathogens | NIAID: National Institute of Allergy and Infectious Diseases. https:\/\/www.niaid.nih.gov\/research\/niaid-biodefense-pathogens (NAID, 2024)."},{"key":"1147_CR15","unstructured":"WHO Expert Consultation on Rabies: WHO TRS N\u00b01012 Third report. https:\/\/www.who.int\/publications\/i\/item\/WHO-TRS-1012."},{"key":"1147_CR16","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3390\/v13081516","volume":"13","author":"SM Moore","year":"2021","unstructured":"Moore, S. M. Challenges of rabies serology: defining context of interpretation. Viruses 13, 1516 (2021).","journal-title":"Viruses"},{"key":"1147_CR17","doi-asserted-by":"crossref","unstructured":"Rao, A. K. Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies: recommendations of the advisory committee on immunization practices \u2014 United States, 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 619\u2013627 (2022).","DOI":"10.15585\/mmwr.mm7118a2"},{"key":"1147_CR18","doi-asserted-by":"publisher","first-page":"e0186998","DOI":"10.1371\/journal.pone.0186998","volume":"12","author":"S Reiss","year":"2017","unstructured":"Reiss, S. et al. Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. PLoS ONE 12, e0186998 (2017).","journal-title":"PLoS ONE"},{"key":"1147_CR19","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","volume":"185","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434\u20132451 (2022).","journal-title":"Cell"},{"key":"1147_CR20","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1016\/j.vaccine.2021.08.092","volume":"39","author":"S Pallikkuth","year":"2021","unstructured":"Pallikkuth, S., Williams, E., Pahwa, R., Hoffer, M. & Pahwa, S. Association of Flu specific and SARS-CoV-2 specific CD4 T cell responses in SARS-CoV-2 infected asymptomatic heath care workers. Vaccine 39, 6019\u20136024 (2021).","journal-title":"Vaccine"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01147-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T22:03:36Z","timestamp":1758751416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01147-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1147"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01147-4","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: C.J.M., S.J.M-S., G.P., N.S.W., A.J.G., Z.G., and P.A. are employees of Replicate Bioscience Inc. All other authors declare no competing interests. The sponsor was involved in all stages of the study including design, analysis and manuscript writing.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"392"}}